Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cell Adoptive Therapy After Haplo-HCT in AML
NCT02782546Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2017
- Primary completion
- Oct 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytokine-induced memory-like natural killer cells and nogapendekin alfa inbakicept in acute myeloid leukemia (AML) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Leukemia-free Survival Rate at 1 year. Started Jan 2017; status: active, not recruiting.
02
Drugs
cytokine-induced memory-like natural killer cellsnogapendekin alfa inbakicept
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02782546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782546.